Survival and Toxicity Trade-Offs With Anthracycline-Based Induction vs Non-Anthracycline Therapy in Newly Diagnosed Acute Myeloid Leukemia: A Real-World Propensity-Matched Analysis (SOHO 2026) - Sep 1, 2026 - Abstract #AML-1360; "Anthracycline cohort (n = 9727): daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone. Nonanthracycline cohort (n = 6649): azacitidine, decitabine, venetoclax, glasdegib, gilteritinib, enasidenib, ivosidenib, midostaurin; anthracyclines excluded... Anthracycline induction was associated with 27% lower 3-year mortality but higher acute toxicity—36% more hospitalization, 23% bleeding, 13% VTE, 11% MACE—reflecting the risk-benefit profile of intensive induction. Selection of fitter patients with favorable AML biology likely contributes through residual confounding despite PSM. These findings reinforce integrating fitness, cytogenetic/molecular risk, and patient preference into the frontline regimen choice."
Clinical • Real-world • Real-world evidence • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • FLT3
|
|
Sandipta Banerjee MD 1; Chanchal Maheshwari MD 2; Humzah Abbas MBBS 3
|